IN2014MU01194A - - Google Patents

Info

Publication number
IN2014MU01194A
IN2014MU01194A IN1194MU2014A IN2014MU01194A IN 2014MU01194 A IN2014MU01194 A IN 2014MU01194A IN 1194MU2014 A IN1194MU2014 A IN 1194MU2014A IN 2014MU01194 A IN2014MU01194 A IN 2014MU01194A
Authority
IN
India
Prior art keywords
acceptable derivative
pharmaceutical
sulbactam
cefepime
stereoisomer
Prior art date
Application number
Other languages
English (en)
Inventor
Sachin Bhagwat
Mahesh Vithalbhai Patel
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Priority to JP2016558575A priority Critical patent/JP2017508769A/ja
Priority to US15/300,113 priority patent/US20170151221A1/en
Priority to IN1194MU2014 priority patent/IN2014MU01194A/en
Priority to CN201580017231.6A priority patent/CN106900171A/zh
Priority to PCT/IB2015/050268 priority patent/WO2015150926A1/en
Priority to KR1020167027684A priority patent/KR20160130824A/ko
Priority to MX2016012646A priority patent/MX2016012646A/es
Priority to BR112016022439A priority patent/BR112016022439A2/pt
Priority to EP15706531.9A priority patent/EP3125887A1/en
Publication of IN2014MU01194A publication Critical patent/IN2014MU01194A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
IN1194MU2014 2014-03-29 2015-01-14 IN2014MU01194A (enrdf_load_html_response)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2016558575A JP2017508769A (ja) 2014-03-29 2015-01-14 セフェピムまたはスルバクタムを含む医薬組成物
US15/300,113 US20170151221A1 (en) 2014-03-29 2015-01-14 Pharmaceutical compositions comprising cefepime or sulbactam
IN1194MU2014 IN2014MU01194A (enrdf_load_html_response) 2014-03-29 2015-01-14
CN201580017231.6A CN106900171A (zh) 2014-03-29 2015-01-14 包含头孢吡肟或舒巴坦的药物组合物
PCT/IB2015/050268 WO2015150926A1 (en) 2014-03-29 2015-01-14 Pharmaceutical compositions comprising cefepime or sulbactam
KR1020167027684A KR20160130824A (ko) 2014-03-29 2015-01-14 세페파임 또는 술박탐을 포함하는 제약학적 조성물
MX2016012646A MX2016012646A (es) 2014-03-29 2015-01-14 Composiciones farmaceuticas que comprenden agentes antibacterianos.
BR112016022439A BR112016022439A2 (pt) 2014-03-29 2015-01-14 Composições farmacêuticas que compreendem cefepima ou sulbactama
EP15706531.9A EP3125887A1 (en) 2014-03-29 2015-01-14 Pharmaceutical compositions comprising cefepime or sulbactam

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1194MU2014 IN2014MU01194A (enrdf_load_html_response) 2014-03-29 2015-01-14

Publications (1)

Publication Number Publication Date
IN2014MU01194A true IN2014MU01194A (enrdf_load_html_response) 2015-10-02

Family

ID=54239460

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1194MU2014 IN2014MU01194A (enrdf_load_html_response) 2014-03-29 2015-01-14

Country Status (9)

Country Link
US (1) US20170151221A1 (enrdf_load_html_response)
EP (1) EP3125887A1 (enrdf_load_html_response)
JP (1) JP2017508769A (enrdf_load_html_response)
KR (1) KR20160130824A (enrdf_load_html_response)
CN (1) CN106900171A (enrdf_load_html_response)
BR (1) BR112016022439A2 (enrdf_load_html_response)
IN (1) IN2014MU01194A (enrdf_load_html_response)
MX (1) MX2016012646A (enrdf_load_html_response)
WO (1) WO2015150926A1 (enrdf_load_html_response)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230365561A1 (en) * 2020-09-01 2023-11-16 Ningxia Academy Of Agricul Ture And Forestry Sciences Beta-lactamase inhibitors and their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101244362B1 (ko) * 2004-12-02 2013-03-18 비너스 레머디스 리미티드 주사제에 유용한 베타-락타마제 억제제를 이용한 베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물
EP3412289A1 (en) * 2011-05-28 2018-12-12 Wockhardt Limited Antibacterial compositions
JP5809750B2 (ja) * 2011-07-26 2015-11-11 ウォックハート リミテッド β−ラクタム抗生物質、スルバクタム及びβ−ラクタマーゼ阻害薬を含む医薬組成物
MX338610B (es) * 2011-07-26 2016-04-25 Wockhardt Ltd Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.
DK2748165T3 (en) * 2011-08-27 2016-12-19 Wockhardt Ltd 1,6-diazabicyclo [3,2,1] octane-7-ON DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
RU2614418C2 (ru) * 2012-08-25 2017-03-28 Вокхардт Лимитед Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение для лечения бактериальных инфекций
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

Also Published As

Publication number Publication date
JP2017508769A (ja) 2017-03-30
BR112016022439A2 (pt) 2017-08-15
EP3125887A1 (en) 2017-02-08
CN106900171A (zh) 2017-06-27
MX2016012646A (es) 2016-10-28
KR20160130824A (ko) 2016-11-14
US20170151221A1 (en) 2017-06-01
WO2015150926A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
PH12018500591B1 (en) Heterocyclic compounds and uses thereof
PH12016502255A1 (en) Combination
TW201613911A (en) Heterocyclic compounds and uses thereof
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
PH12018500061A1 (en) Oxysterols and methods of use thereof
EP4279071A3 (en) Novel cannabinoid formulations
MX2016011992A (es) Derivados de piperidina-diona.
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2018014813A (es) Composiciones antibacterianas.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
NZ783808A (en) Crystalline forms of c21h22cl2n4o2
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
NZ739518A (en) Compounds useful for inhibiting ror-gamma-t
IN2014CH00840A (enrdf_load_html_response)
IN2014MU00859A (enrdf_load_html_response)
TW201613898A (en) Benzofuran analogue as NS4B inhibitor
IN2013MU03308A (enrdf_load_html_response)
IN2013MU03421A (enrdf_load_html_response)
IN2013MU03704A (enrdf_load_html_response)
MY202239A (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
IN2013MU03422A (enrdf_load_html_response)
IN2013MU03309A (enrdf_load_html_response)
IN2014MU01194A (enrdf_load_html_response)
MX2018010652A (es) Composiciones farmaceuticas.